Gene transfer for erectile dysfunction

Will this novel therapy be accepted by urologists?

Arnold Melman, Lorraine Rojas, George Christ

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Purpose of review: The purpose of this review is to update the results of the only phase 1 erectile dysfunction gene transfer trial and based upon those results present the outcome of a web-based survey that studied whether or not knowledgeable in the field urologists would use gene transfer in their patients once approved for use by the US Food and Drug Administration. Recent findings: The results of the clinical trials showed no transfer-related serious adverse events. The response to 10 questions of a web-based survey indicates that gene transfer as a first or second-line therapy for practicing urologists would be well accepted. Summary: Practicing, experienced urologists, after the US Food and Drug Administration approval, are willing to employ gene transfer therapies in their patients, be it men who have failed or dissatisfied with other treatments or as shown in up to one-third of men as a first therapy. That outcome portends for rapid adaptation and active participation into the medical practice for maxi-K or other specific gene transfer, stem cell, or combinations that will be developed in the future.

Original languageEnglish (US)
Pages (from-to)595-600
Number of pages6
JournalCurrent Opinion in Urology
Volume19
Issue number6
DOIs
StatePublished - Nov 2009

Fingerprint

Erectile Dysfunction
Genes
Drug Approval
United States Food and Drug Administration
Therapeutics
Genetic Therapy
Stem Cells
Clinical Trials
Food
Urologists
Surveys and Questionnaires

Keywords

  • Erectile dysfunction
  • Gene transfer
  • Maxi-K
  • Naked DNA

ASJC Scopus subject areas

  • Urology

Cite this

Gene transfer for erectile dysfunction : Will this novel therapy be accepted by urologists? / Melman, Arnold; Rojas, Lorraine; Christ, George.

In: Current Opinion in Urology, Vol. 19, No. 6, 11.2009, p. 595-600.

Research output: Contribution to journalArticle

Melman, Arnold ; Rojas, Lorraine ; Christ, George. / Gene transfer for erectile dysfunction : Will this novel therapy be accepted by urologists?. In: Current Opinion in Urology. 2009 ; Vol. 19, No. 6. pp. 595-600.
@article{970f107316014db8876c323be74aeba2,
title = "Gene transfer for erectile dysfunction: Will this novel therapy be accepted by urologists?",
abstract = "Purpose of review: The purpose of this review is to update the results of the only phase 1 erectile dysfunction gene transfer trial and based upon those results present the outcome of a web-based survey that studied whether or not knowledgeable in the field urologists would use gene transfer in their patients once approved for use by the US Food and Drug Administration. Recent findings: The results of the clinical trials showed no transfer-related serious adverse events. The response to 10 questions of a web-based survey indicates that gene transfer as a first or second-line therapy for practicing urologists would be well accepted. Summary: Practicing, experienced urologists, after the US Food and Drug Administration approval, are willing to employ gene transfer therapies in their patients, be it men who have failed or dissatisfied with other treatments or as shown in up to one-third of men as a first therapy. That outcome portends for rapid adaptation and active participation into the medical practice for maxi-K or other specific gene transfer, stem cell, or combinations that will be developed in the future.",
keywords = "Erectile dysfunction, Gene transfer, Maxi-K, Naked DNA",
author = "Arnold Melman and Lorraine Rojas and George Christ",
year = "2009",
month = "11",
doi = "10.1097/MOU.0b013e3283314985",
language = "English (US)",
volume = "19",
pages = "595--600",
journal = "Current Opinion in Urology",
issn = "0963-0643",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Gene transfer for erectile dysfunction

T2 - Will this novel therapy be accepted by urologists?

AU - Melman, Arnold

AU - Rojas, Lorraine

AU - Christ, George

PY - 2009/11

Y1 - 2009/11

N2 - Purpose of review: The purpose of this review is to update the results of the only phase 1 erectile dysfunction gene transfer trial and based upon those results present the outcome of a web-based survey that studied whether or not knowledgeable in the field urologists would use gene transfer in their patients once approved for use by the US Food and Drug Administration. Recent findings: The results of the clinical trials showed no transfer-related serious adverse events. The response to 10 questions of a web-based survey indicates that gene transfer as a first or second-line therapy for practicing urologists would be well accepted. Summary: Practicing, experienced urologists, after the US Food and Drug Administration approval, are willing to employ gene transfer therapies in their patients, be it men who have failed or dissatisfied with other treatments or as shown in up to one-third of men as a first therapy. That outcome portends for rapid adaptation and active participation into the medical practice for maxi-K or other specific gene transfer, stem cell, or combinations that will be developed in the future.

AB - Purpose of review: The purpose of this review is to update the results of the only phase 1 erectile dysfunction gene transfer trial and based upon those results present the outcome of a web-based survey that studied whether or not knowledgeable in the field urologists would use gene transfer in their patients once approved for use by the US Food and Drug Administration. Recent findings: The results of the clinical trials showed no transfer-related serious adverse events. The response to 10 questions of a web-based survey indicates that gene transfer as a first or second-line therapy for practicing urologists would be well accepted. Summary: Practicing, experienced urologists, after the US Food and Drug Administration approval, are willing to employ gene transfer therapies in their patients, be it men who have failed or dissatisfied with other treatments or as shown in up to one-third of men as a first therapy. That outcome portends for rapid adaptation and active participation into the medical practice for maxi-K or other specific gene transfer, stem cell, or combinations that will be developed in the future.

KW - Erectile dysfunction

KW - Gene transfer

KW - Maxi-K

KW - Naked DNA

UR - http://www.scopus.com/inward/record.url?scp=70350066071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350066071&partnerID=8YFLogxK

U2 - 10.1097/MOU.0b013e3283314985

DO - 10.1097/MOU.0b013e3283314985

M3 - Article

VL - 19

SP - 595

EP - 600

JO - Current Opinion in Urology

JF - Current Opinion in Urology

SN - 0963-0643

IS - 6

ER -